{"filings":[{"id":863236,"accession_number":"0001193125-26-257733","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2026-06-04T21:09:05+00:00","items":["8.01","9.01"],"status":"ready","headline":"Jade Biosciences prices $150M public offering of 10M shares at $15/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced public offering of 10,000,000 shares of common stock at $15.00 per share for gross proceeds of $150.0M.","Net proceeds expected ~$140.3M (~$161.5M if underwriters’ 30-day option for 1.5M additional shares is exercised).","Intends use net proceeds for clinical trials, preclinical studies, manufacturing, R&D, capex, working capital, and general corporate purposes.","Jefferies, TD Cowen, UBS Investment Bank acting as joint book-running managers; offering expected to close June 5, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":759677,"accession_number":"0001193125-26-249763","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2026-06-01T11:55:09+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Jade Biosciences reports Phase 1 interim data: JADE101 shows ~70% IgA reduction, favorable safety, differentiated PK","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean IgA reduction ~70% from baseline, sustained at 12 weeks with single 700 mg dose; steady-state simulation supports Q12W dosing.","JADE101 estimated 379-fold more potent than sibeprenlimab and 26-fold more potent than povetacicept in IgA-lowering.","Favorable safety: no serious AEs, no discontinuations, no hypogammaglobulinemia; most common AEs were headache (25%), URTI (21.9%).","Half-life at steady state ~8.7x longer than povetacicept and ~2.6x longer than sibeprenlimab, supporting convenient dosing (4 injections/year).","Phase 2 JUNIPER trial ongoing; registrational Phase 3 planned for H1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95529,"accession_number":"0001193125-26-211973","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jade Biosciences Q1 net loss $40.4M, cash $311.3M; pipeline and CMO appointment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $40.4M for Q1 2026 vs $38.2M in Q1 2025, driven by higher R&D and G&A costs.","Cash, equivalents, and investments $311.3M at March 31, 2026; funding expected into first half 2028.","JADE101 Phase 1 interim biomarker data to be presented at ERA Congress; Phase 2 in IgAN expected Q2 2026.","JADE201 Phase 1 trial in rheumatoid arthritis expected to start Q2 2026; interim data in 2027.","Appointed Edward R. Conner, M.D., as CMO; promoted Andrew King to President, R&D."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95528,"accession_number":"0001193125-26-168351","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Andrew King promoted to President, R&D at Jade Biosciences","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew King previously CSO and Head of R&D appointed President Research & Development effective April 18 2026","No changes to Dr Kings compensation were made in connection with the appointment","King holds BVMS and Ph.D degrees and continues to lead R&D with expanded title"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95527,"accession_number":"0001193125-26-140091","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Jade Biosciences approves 2026 Inducement Plan, reserving 1.75M shares for new hires","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 2026 Employment Inducement Stock Incentive Plan, effective March 31, 2026.","1,750,000 shares of common stock reserved for issuance under the plan.","Awards limited to new employees as inducement material to hire, per Nasdaq Rule 5635(c)(4).","Plan substantially similar to 2025 Stock Incentive Plan but no incentive stock options allowed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108669,"accession_number":"0001193125-26-094967","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jade Biosciences reports $336M cash; JADE101 Phase 1 data expected Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and investments of $336.2M as of Dec 31, 2025; runway into first half 2028.","Q4 2025 net loss $31.9M vs $30.1M Q4 2024; full year net loss $127.4M.","JADE101 Phase 1 interim data expected Q2 2026; Phase 2 IgA nephropathy trial to start mid-2026.","JADE201 (anti-BAFF-R) Phase 1 in rheumatoid arthritis expected Q2 2026; interim data 2027.","Raised ~$180M in Q4 2025 private placements from new and existing investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108668,"accession_number":"0001193125-26-001502","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Jade Biosciences reports $336M cash; outlines 2026 pipeline milestones including JADE101 Phase 2","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and investments ~$336M as of Dec 31, 2025; funds operations into H1 2028.","JADE101 Phase 1 interim data expected H1 2026; Phase 2 in IgAN to start mid-2026 with preliminary data in 2027.","JADE201 (anti-BAFF-R) first-in-human study in RA expected Q2 2026; interim data in 2027.","JADE301 nominated; preclinical; Phase 1 expected H1 2027; details disclosed H2 2026.","Company to present at J.P. Morgan Healthcare Conference on Jan 15, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125117,"accession_number":"0001193125-25-318436","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Jade Biosciences raises $45M in private placement with BB Biotech at $14/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 3,214,286 shares at $14.00 per share for gross proceeds of ~$45M.","Purchaser is BB Biotech; closing expected on or about December 16, 2025.","Net proceeds to fund R&D, general corporate expenses, and working capital.","Registration rights agreement filed; resale registration statement required within 45 days post-closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125116,"accession_number":"0001193125-25-281498","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Jade Biosciences Q3 net loss $25.2M; cash runway into H1 2028 after $135M placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 net loss of $25.2M vs $16.3M loss in Q3 2024; R&D expenses $22.0M, G&A $5.4M.","Cash, equivalents, and investments $198.9M at Sep 30; pro-forma ~$325.6M after $135M private placement closed in October.","Phase 1 trial of JADE101 (anti-APRIL for IgAN) enrolled; interim biomarker data expected H1 2026.","Unveiled JADE201 (anti-BAFF-R); first-in-human trial in rheumatoid arthritis planned for H1 2026.","Private placement of $135M extended cash runway into first half of 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125115,"accession_number":"0001193125-25-232562","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Jade Biosciences raises $135M in PIPE; unveils BAFF-R candidate JADE201","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement raises ~$135M gross via 13.37M shares at $9.14 and pre-funded warrants; close expected Oct 8, 2025.","Pro forma shares outstanding ~67.4M; cash runway extended into first half 2028.","Licenses BAFF-R antibodies from Paragon Therapeutics; up to $22M in milestones plus low-to-mid-single-digit royalties.","JADE201 is a half-life extended afucosylated anti-BAFF-R mAb; Phase 1 in rheumatoid arthritis expected H1 2026.","NHP data shows ~2-fold half-life increase vs ianalumab and sustained B-cell depletion after single SC dose."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141825,"accession_number":"0001193125-25-198777","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Chief Medical Officer Hetal Kocinsky departs; Andrew King to lead clinical programs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hetal Kocinsky, M.D., left CMO role effective Sept 9, 2025.","Company expects separation agreement: 12 months base salary plus 12 months COBRA premium payment.","Dr. Andrew King, Ph.D, CSO & Head of R&D, will continue leading scientific and clinical programs.","No successor named for CMO role; no details on search process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141824,"accession_number":"0001193125-25-179828","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jade Biosciences Q2 net loss $32.1M; cash $220.9M; JADE101 Phase 1 starts Q3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $32.1M for Q2 2025; R&D expense $22.5M, G&A $5.2M; non-cash stock comp $4.0M.","Cash and cash equivalents of $220.9M as of June 30, 2025; expected runway through 2027.","JADE101 preclinical data presented; Phase 1 healthy-volunteer study to begin Q3 2025 with interim data H1 2026.","Appointed Brad Dahms as CFO; previously CFO at IDRx, Theseus, Selecta.","JADE201 development candidate from JADE-002 program on track for clinic in H1 2026; details expected H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141823,"accession_number":"0001193125-25-153427","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Jade Biosciences appoints Brad Dahms as CFO, enters manufacturing agreement with Patheon for JADE101","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brad Dahms appointed CFO effective July 14, 2025; base salary $500K, target bonus 40%, option for 526,000 shares vesting over 4 years.","Patheon MSA covers cGMP manufacturing for JADE101 and future programs; initial 5-year term with auto-renewal; non-cancellable fees per project.","Dahms previously CFO of IDRx (sold to GSK), Theseus (sold to Concentra), and Selecta; brings 15 years biotech and investment banking experience.","Company advancing JADE101 into clinic this year for IgA nephropathy; recent Nasdaq listing and private financing provide momentum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159743,"accession_number":"0001193125-25-119856","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.01","2.02","7.01","9.01"],"status":"ready","headline":"Jade Biosciences Q1 2025 net loss $38.2M, cash $49.9M, merger closed Apr 28","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $38.2M for Q1 2025; R&D expenses $20.0M, G&A $3.4M; change in fair value of convertible notes added $15.4M to other expense.","Cash and equivalents $49.9M as of March 31, 2025, down from $69.4M at Dec 31, 2024; expects existing cash plus $334.2M from Pre-Closing Financing to fund operations for at least 12 months.","Merger with Aerovate Therapeutics completed on April 28, 2025; combined entity renamed Jade Biosciences, Inc., trades on Nasdaq as JBIO.","Lead candidate JADE-101 (APRIL-targeting antibody) for IgA nephropathy; two preclinical programs JADE-002 and JADE-003 in antibody discovery.","Company had $123M in convertible notes payable (including $26M related party) and $2M warrant liability as of March 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159742,"accession_number":"0001193125-25-110004","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["1.01","2.01","5.02","9.01","2.02","3.03","4.01","5.01","5.03","5.05","5.06","7.01"],"status":"ready","headline":"Jade Biosciences completes reverse merger with Aerovate; former Aerovate holders own ~1.4%","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed April 28, 2025; Aerovate stockholders received ~$69.6M special dividend ($2.40 pre-split) and ~1.4% of combined entity.","Jade securityholders own ~98.6% of combined company; gross proceeds ~$334.2M raised including $95M convertible note conversion.","Aerovate 1-for-35 reverse stock split effective prior to close; combined company renamed Jade Biosciences, Inc., ticker JBIO.","Post-merger outstanding: 32.2M common shares, 7.8M pre-funded warrants, and 12.6M shares underlying Series A Preferred Stock.","Unaudited pro forma combined financials filed; business focus on autoimmune disease therapies from Paragon Therapeutics license."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159741,"accession_number":"0001193125-25-103761","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Jade Biosciences provides updated corporate presentation; no material new details disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company changed name from Aerovate Therapeutics to Jade Biosciences, effective prior to this filing; trades under ticker JBIO on Nasdaq.","Updated corporate presentation posted on company website on April 29, 2025; no financial or operational updates provided in the 8-K or exhibit.","Presentation appears to be a Company Overview slide with disclaimers; no new specific data (revenue, pipeline, guidance) disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159740,"accession_number":"0001558370-25-005278","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aerovate moves special dividend payment to April 28, contingent on merger close","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special cash dividend of $2.40/share ($69.6M aggregate) record date April 25, payment moved to April 28.","Payment is conditioned upon closing of merger with Jade Biosciences, expected April 28.","Closing requires Nasdaq Capital Market listing approval for combined company.","Merger agreement was previously disclosed on October 30, 2024; transaction structure unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159739,"accession_number":"0001104659-25-036566","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["5.07","7.01","8.01","9.01"],"status":"ready","headline":"Aerovate stockholders approve merger with Jade Biosciences, 1-for-35 reverse split","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All eight proposals approved at April 16 special meeting, including merger and reverse stock split.","Board approves 1-for-35 reverse split, reducing outstanding from ~30M to ~0.8M shares.","Special cash dividend of $69.6M ($2.40/share) unaffected; record date April 25.","Combined company to trade as JBIO on Nasdaq starting April 29 after merger close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159738,"accession_number":"0001104659-25-033397","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aerovate declares special $2.40/share cash dividend ($69.6M total) conditional on Jade Biosciences merger","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Special cash dividend of $69.6M ($2.40/share) declared, payable to holders of record as of April 25, 2025.","Dividend conditioned on merger with Jade Biosciences closing, expected on or about April 28, 2025.","Stockholders to vote on merger at special meeting on April 16, 2025; dividend payment date April 29, 2025.","Dividend expected to be non-taxable return of capital; company has no current or accumulated earnings and profits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159737,"accession_number":"0001104659-25-033200","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aerovate discloses stockholder lawsuits and demand letters over merger with Jade Biosciences","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Two lawsuits filed March 27, 2025 in NY state court alleging misrepresentations in S-4; seek injunctive relief or damages.","Ten demand letters received Dec 14, 2024 – Apr 9, 2025 requesting additional disclosures in the S-4.","Aerovate voluntarily supplements S-4 with background details on reverse merger process, Wedbush/Lucid engagements, and updated financial tables.","Company denies legal necessity of additional disclosures but adds them to avoid nuisance and delay.","Merger agreement with Jade (reverse merger) remains subject to stockholder vote and closing conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159736,"accession_number":"0001558370-25-004511","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aerovate announces $67.6-69.6M cash dividend range for proposed merger; stockholder vote April 16","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cash dividend expected $67.6-69.6M in aggregate, based on estimated net cash prior to merger closing.","As of April 4, 2025, 28,985,019 shares of common stock outstanding.","Stockholders vote on merger at special meeting scheduled for April 16, 2025 at 9:00 a.m. ET.","Closing expected no later than April 30, 2025, subject to stockholder approval and other conditions.","Dividend expected to be a return of capital, not characterized as dividend for tax purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194787,"accession_number":"0001104659-24-112896","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["1.01","3.02","5.01","5.02","7.01","9.01"],"status":"ready","headline":"Aerovate to merge with Jade Biosciences; Jade holders to own 98.4%","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Aerovate (AVTE) reverse-merges with Jade; pre-merger Jade stockholders receive 98.4% of combined firm; Aerovate holders receive 1.6%.","Concurrent ~$300M PIPE led by existing Jade investors, including conversion of $95M convertible notes.","Aerovate to pay ~$65M cash dividend to its pre-merger stockholders; combined company renamed Jade Biosciences, expects ticker 'JBIO'.","Post-closing board will be six members, all designated by Jade; closing requires stockholder and regulatory approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194786,"accession_number":"0001798749-24-000055","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2024-10-17T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Aerovate regains Nasdaq audit committee compliance by appointing Habib J. Dable","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company notified Nasdaq of noncompliance on Oct 11 due to only two audit committee members after Dr. Katabi's resignation.","Board appointed director Habib J. Dable to the audit committee effective Oct 17, 2024.","With Dable's appointment, Aerovate regained compliance with Nasdaq Listing Rule 5605(c)(2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194785,"accession_number":"0001798749-24-000052","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Maha Katabi resigns from Aerovate board and committees effective Oct 6, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Maha Katabi, Ph.D., resigned from the board, Audit Committee, and Compensation Committee.","Resignation effective October 6, 2024, voluntary and not due to any disagreement with the company.","Board expressed gratitude for Dr. Katabi's service and contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211084,"accession_number":"0001798749-24-000042","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aerovate Therapeutics halts Phase 3 PAH trial, launches strategic alternatives review with Wedbush","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Previously halted enrollment and shut down Phase 3 IMPAHCT trial and long-term extension study.","Now conducting comprehensive review of strategic alternatives to maximize shareholder value.","Engaged Wedbush PacGrow as exclusive strategic financial advisor for the review process.","Alternatives may include acquisition, merger, reverse merger, business combination, or liquidation.","No timetable set and no assurance any transaction will result from the review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211083,"accession_number":"0001798749-24-000039","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K/A","filed_at":"2024-07-01T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Aerovate Therapeutics to reduce nearly all workforce after ending AV-101 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On June 25, 2024, Aerovate began workforce reduction after ending AV-101 clinical program.","First wave: 39 employees (78% of workforce) terminated; nearly all remaining staff to be let go.","Estimated $5.6 million in severance costs, mostly one-time, to be incurred in Q3 and Q4 2024.","Severance contingent on separation agreements with general release of claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229590,"accession_number":"0001798749-24-000036","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Aerovate Therapeutics cuts 78% of workforce after halting AV-101 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduction follows shutdown of Phase 2b/3 trial of AV-101 and long-term extension study.","First wave terminates 39 employees (78% of workforce); nearly all remaining staff to follow.","Estimated severance costs of $5.6 million, expected in Q3 and Q4 2024.","Severance contingent on separation agreement with general release of claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229589,"accession_number":"0001104659-24-072058","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aerovate Phase 2b trial of AV-101 fails primary endpoint; halts Phase 3 and extension","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AV-101 did not meet primary endpoint of PVR improvement at any dose (10, 35, 70 mg BID); p-values all >0.36.","Secondary endpoint 6MWD also showed no meaningful improvement; LS mean differences ranging -11.7 to +1.3 meters.","Company halting enrollment and shutting down Phase 3 IMPAHCT and long-term extension study, per advisory committee.","Cash position ~$100M as of June 15, 2024; CEO calls results unexpected and disappointing.","Full Phase 2b data release timing to be determined; no new clinical path announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229588,"accession_number":"0001798749-24-000033","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aerovate Therapeutics stockholders elect directors and ratify KPMG as auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected David Grayzel, M.D. and Maha Katabi, Ph.D. as Class III directors with 24.4M and 25.9M votes for, respectively.","Ratification of KPMG LLP as independent auditor for FY 2024 was approved with 28,074,033 votes for, 511 against, 105 abstain.","The meeting was held on June 5, 2024; 28,737,381 shares were outstanding and entitled to vote as of April 12, 2024 record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229587,"accession_number":"0001798749-24-000029","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aerovate reports Q1 2024 net loss $23.2M; cash $99.3M; Phase 2b topline data expected June 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $23.2M for Q1 2024 vs $16.5M in Q1 2023; R&D expenses $20.1M, G&A $4.5M.","Cash, equivalents and short-term investments $99.3M at March 31, 2024; raised net $23.6M via ATM in April.","Topline data from Phase 2b portion of IMPAHCT trial of AV-101 in PAH expected in June 2024.","Enrollment continues in Phase 3 portion of IMPAHCT; over 120 sites in 20+ countries.","Cash runway into 2026 based on current operating plan."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248124,"accession_number":"0001798749-24-000018","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aerovate Therapeutics furnishes corporate presentation; no material news disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed under Item 7.01 as Regulation FD disclosure; presentation used for investor meetings starting March 27, 2024.","Presentation focuses on pipeline for pulmonary arterial hypertension; no new clinical or financial data provided.","No specific numbers, milestones, or guidance changes were included in the exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248123,"accession_number":"0001798749-24-000014","cik":1798749,"company_name":"Jade Biosciences, Inc.","ticker":"JBIO","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aerovate reports 2023 net loss $75.5M; Phase 2b topline data for AV-101 in PAH expected June 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and short-term investments totaled $122.4M at Dec 31, 2023; cash runway expected into 2026.","Net loss for 2023 was $75.5M compared to $51.5M in 2022; R&D expenses rose to $64.2M from $38.6M.","Phase 2b portion of IMPAHCT trial enrolled 202 patients; topline data expected in June 2024.","First patient enrolled in Phase 3 portion of IMPAHCT in November 2023; over 120 clinical sites participating.","Board expanded with Habib Dable and Donald Santel; Dable appointed Chair in March 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1045195347.7081397,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}